Need professional-grade analysis? Visit stockanalysis.com
$159.34M
N/A
N/A
N/A
Sagimet Biosciences Inc. Series A Common Stock (SGMT) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $5.91, down 8.66% from the previous close.
Over the past year, SGMT has traded between a low of $2.77 and a high of $10.24. The stock has gained 113.0% over this period. It is currently 42.3% below its 52-week high.
Sagimet Biosciences Inc. Series A Common Stock has a market capitalization of $159.34M.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Side-by-side comparison against top Healthcare peers.